Wei Zheng

List of Publications by Year in Descending Order

255 papers	8,878 citations	47 h-index	85 g-index
273 ext. papers	10,780 ext. citations	6.1 avg, IF	6.07 L-index

#	Paper	IF	Citations
255	SARS-CoV-2 Nucleocapsid Protein TR-FRET Assay Amenable to High Throughput Screening.. *ACS Pharmacology and Translational Science*, **2022**, 5, 8-19	5.9	0
254	Targeting the Fusion Process of SARS-CoV-2 Infection by Small Molecule Inhibitors.. *MBio*, **2022**, e0323821	7.8	1
253	A high throughput screening assay for inhibitors of SARS-CoV-2 pseudotyped particle entry.. *SLAS Discovery*, **2022**,	3.4	4
252	iPS-derived neural stem cells for disease modeling and evaluation of therapeutics for mucopolysaccharidosis type II.. *Experimental Cell Research*, **2022**, 412, 113007	4.2	0
251	c-Abl Activation Linked to Autophagy-Lysosomal Dysfunction Contributes to Neurological Impairment in Niemann-Pick Type A Disease.. *Frontiers in Cell and Developmental Biology*, **2022**, 10, 844297	5.7	0
250	Glucocerebrosidase Mutations Cause Mitochondrial and Lysosomal Dysfunction in Parkinson's Disease: Pathogenesis and Therapeutic Implications.. *Frontiers in Aging Neuroscience*, **2022**, 14, 851135	5.3	0
249	Mitoxantrone modulates a heparan sulfate-spike complex to inhibit SARS-CoV-2 infection.. *Scientific Reports*, **2022**, 12, 6294	4.9	0
248	Endoclip papillaplasty restores sphincter of Oddi function: Pilot study. *Digestive Endoscopy*, **2021**, 33, 962-969	3.7	1
247	Mining of high throughput screening database reveals AP-1 and autophagy pathways as potential targets for COVID-19 therapeutics. *Scientific Reports*, **2021**, 11, 6725	4.9	12
246	Identification of Antifungal Compounds against Multidrug-Resistant Candida auris Utilizing a High-Throughput Drug-Repurposing Screen. *Antimicrobial Agents and Chemotherapy*, **2021**, 65,	5.9	4
245	SENP1-mediated deSUMOylation of JAK2 regulates its kinase activity and platinum drug resistance. *Cell Death and Disease*, **2021**, 12, 341	9.8	3
244	Generation of an induced pluripotent stem cell line (TRNDi030-A) from a patient with Farber disease carrying a homozygous p. Y36C (c. 107 A>G) mutation in ASAH1. *Stem Cell Research*, **2021**, 53, 102387	1.6	1
243	Application of niclosamide and analogs as small molecule inhibitors of Zika virus and SARS-CoV-2 infection. *Bioorganic and Medicinal Chemistry Letters*, **2021**, 40, 127906	2.9	3
242	Viral Proteases as Targets for Coronavirus Disease 2019 Drug Development. *Journal of Pharmacology and Experimental Therapeutics*, **2021**, 378, 166-172	4.7	6
241	High-throughput screening assays for SARS-CoV-2 drug development: Current status and future directions. *Drug Discovery Today*, **2021**, 26, 2439-2444	8.8	4
240	Generation of Alagille syndrome derived induced pluripotent stem cell line carrying heterozygous mutation in the JAGGED-1 gene at splicing site (Chr20: 10,629,709C>A) before exon 11. *Stem Cell Research*, **2021**, 53, 102366	1.6	0
239	Drug combination therapy for emerging viral diseases. *Drug Discovery Today*, **2021**, 26, 2367-2376	8.8	11

238	Enrichment of NPC1-deficient cells with the lipid LBPA stimulates autophagy, improves lysosomal function, and reduces cholesterol storage. *Journal of Biological Chemistry*, **2021**, 297, 100813	5.4	4
237	Generation of an induced pluripotent stem cell line (TRNDi031-A) from a patient with Alagille syndrome type 1 carrying a heterozygous p. C312X (c. 936□T▷□A) mutation in JAGGED-1. *Stem Cell Research*, **2021**, 54, 102447	1.6	0
236	Discovery of Small Molecule Entry Inhibitors Targeting the Fusion Peptide of SARS-CoV-2 Spike Protein. *ACS Medicinal Chemistry Letters*, **2021**, 12, 1267-1274	4.3	5
235	Generation of an induced pluripotent stem cell line (TRNDi012-B) from Fibrodysplasia Ossificans Progressiva (FOP) patient carrying a heterozygous mutation c. 617G□▷□A in the ACVR1 gene. *Stem Cell Research*, **2021**, 54, 102424	1.6	
234	Effects of SARS-CoV-2 mutations on protein structures and intraviral protein-protein interactions. *Journal of Medical Virology*, **2021**, 93, 2132-2140	19.7	48
233	Synergistic and Antagonistic Drug Combinations against SARS-CoV-2. *Molecular Therapy*, **2021**, 29, 873-885	11.7	29
232	The SARS-CoV-2 Cytopathic Effect Is Blocked by Lysosome Alkalizing Small Molecules. *ACS Infectious Diseases*, **2021**, 7, 1389-1408	5.5	39
231	Structural interaction between DISC1 and ATF4 underlying transcriptional and synaptic dysregulation in an iPSC model of mental disorders. *Molecular Psychiatry*, **2021**, 26, 1346-1360	15.1	13
230	An Integrated Systems Biology Approach Identifies the Proteasome as A Critical Host Machinery for ZIKV and DENV Replication. *Genomics, Proteomics and Bioinformatics*, **2021**, 19, 108-122	6.5	3
229	Biological activity-based modeling identifies antiviral leads against SARS-CoV-2. *Nature Biotechnology*, **2021**, 39, 747-753	44.5	14
228	An induced pluripotent stem cell line (NCATS-CL9075) from a patient carrying compound heterozygote mutations, p.R390P and p.L318P, in the NGLY1 gene. *Stem Cell Research*, **2021**, 54, 102400	1.6	
227	Therapeutics Development for Alagille Syndrome. *Frontiers in Pharmacology*, **2021**, 12, 704586	5.6	3
226	Protein structural features predict responsiveness to pharmacological chaperone treatment for three lysosomal storage disorders. *PLoS Computational Biology*, **2021**, 17, e1009370	5	0
225	Hybrid Approach Reveals Novel Inhibitors of Multiple SARS-CoV-2 Variants. *ACS Pharmacology and Translational Science*, **2021**, 4, 1675-1688	5.9	2
224	Generation of two gene corrected human isogenic iPSC lines (NCATS-CL6104 and NCATS-CL6105) from a patient line (NCATS-CL6103) carrying a homozygous p.R401X mutation in the NGLY1 gene using CRISPR/Cas9. *Stem Cell Research*, **2021**, 56, 102554	1.6	1
223	Disease modeling for Mucopolysaccharidosis type IIIB using patient derived induced pluripotent stem cells. *Experimental Cell Research*, **2021**, 407, 112785	4.2	2
222	Identification of potent SENP1 inhibitors that inactivate SENP1/JAK2/STAT signaling pathway and overcome platinum drug resistance in ovarian cancer.. *Clinical and Translational Medicine*, **2021**, 11, e649	5.7	2
221	Zika Virus-Induced Neuronal Apoptosis via Increased Mitochondrial Fragmentation. *Frontiers in Microbiology*, **2020**, 11, 598203	5.7	14

220	An induced pluripotent stem cell line (TRNDi001-D) from a Niemann-Pick disease type C1 (NPC1) patient carrying a homozygous p. I1061T (c. 3182T>C) mutation in the NPC1 gene. *Stem Cell Research*, **2020**, 44, 101737	1.6	3
219	Modeling CNS Involvement in Pompe Disease Using Neural Stem Cells Generated from Patient-Derived Induced Pluripotent Stem Cells. *Cells*, **2020**, 10,	7.9	2
218	The SARS-CoV-2 cytopathic effect is blocked with autophagy modulators **2020**,		34
217	An OpenData portal to share COVID-19 drug repurposing data in real time **2020**,		42
216	Discovery of Synergistic and Antagonistic Drug Combinations against SARS-CoV-2 In Vitro **2020**,		7
215	Identifying SARS-CoV-2 entry inhibitors through drug repurposing screens of SARS-S and MERS-S pseudotyped particles **2020**,		9
214	Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs **2020**,		6
213	Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-throughput Screening **2020**,		7
212	Massive-scale biological activity-based modeling identifies novel antiviral leads against SARS-CoV-2 **2020**,		5
211	Human Pluripotent Stem Cell-Derived Neural Cells and Brain Organoids Reveal SARS-CoV-2 Neurotropism **2020**,		13
210	Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2 **2020**,		13
209	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. *Antiviral Research*, **2020**, 173, 104667	10.8	6
208	Four induced pluripotent stem cell lines (TRNDi021-C, TRNDi023-D, TRNDi024-D and TRNDi025-A) generated from fibroblasts of four healthy individuals. *Stem Cell Research*, **2020**, 49, 102011	1.6	1
207	Development of a High-Throughput Homogeneous AlphaLISA Drug Screening Assay for the Detection of SARS-CoV-2 Nucleocapsid. *ACS Pharmacology and Translational Science*, **2020**, 3, 1233-1241	5.9	4
206	RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery. *SLAS Discovery*, **2020**, 25, 1141-1151	3.4	64
205	Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs in vitro. *Cell Discovery*, **2020**, 6, 80	22.3	86
204	Drug Discovery Strategies for SARS-CoV-2. *Journal of Pharmacology and Experimental Therapeutics*, **2020**, 375, 127-138	4.7	51
203	Human recombinant lysosomal β-Hexosaminidases produced in Pichia pastoris efficiently reduced lipid accumulation in Tay-Sachs fibroblasts. *American Journal of Medical Genetics, Part C: Seminars in Medical Genetics*, **2020**, 184, 885-895	3.1	0

202	Identifying SARS-CoV-2 Entry Inhibitors through Drug Repurposing Screens of SARS-S and MERS-S Pseudotyped Particles. *ACS Pharmacology and Translational Science*, **2020**, 3, 1165-1175	5.9	42
201	Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening. *ACS Pharmacology and Translational Science*, **2020**, 3, 1008-1016	5.9	76
200	Cell-Based No-Wash Fluorescence Assays for Compound Screens Using a Fluorescence Cytometry Plate Reader. *Journal of Pharmacology and Experimental Therapeutics*, **2020**, 374, 500-511	4.7	
199	Human Pluripotent Stem Cell-Derived Neural Cells and Brain Organoids Reveal SARS-CoV-2 Neurotropism Predominates in Choroid Plexus Epithelium. *Cell Stem Cell*, **2020**, 27, 937-950.e9	18	151
198	Torin 2 Derivative, NCATS-SM3710, Has Potent Multistage Antimalarial Activity through Inhibition of Phosphatidylinositol 4-Kinase (PI4KIII). *ACS Pharmacology and Translational Science*, **2020**, 3, 948-964	5.9	8
197	Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2. *Frontiers in Pharmacology*, **2020**, 11, 592737	5.6	39
196	Improving therapy of severe infections through drug repurposing of synergistic combinations. *Current Opinion in Pharmacology*, **2019**, 48, 92-98	5.1	27
195	Induced pluripotent stem cells for neural drug discovery. *Drug Discovery Today*, **2019**, 24, 992-999	8.8	43
194	-Tocopherol Effect on Endocytosis and Its Combination with Enzyme Replacement Therapy for Lysosomal Disorders: A New Type of Drug Interaction?. *Journal of Pharmacology and Experimental Therapeutics*, **2019**, 370, 823-833	4.7	2
193	Pharmacological analysis of CFTR variants of cystic fibrosis using stem cell-derived organoids. *Drug Discovery Today*, **2019**, 24, 2126-2138	8.8	9
192	An induced pluripotent stem cell line (TRNDi009-C) from a Niemann-Pick disease type A patient carrying a heterozygous p.L302P (c.905 T>C) mutation in the SMPD1 gene. *Stem Cell Research*, **2019** , 38, 101461	1.6	4
191	Identification of Ezetimibe and Pranlukast as Pharmacological Chaperones for the Treatment of the Rare Disease Mucopolysaccharidosis Type IVA. *Journal of Medicinal Chemistry*, **2019**, 62, 6175-6189	8.3	13
190	Generation of an induced pluripotent stem cell line (TRNDi008-A) from a Hunter syndrome patient carrying a hemizygous 208insC mutation in the IDS gene. *Stem Cell Research*, **2019**, 37, 101451	1.6	4
189	17-Hydroxy Wortmannin Restores TRAILR Response by Ameliorating Increased Beclin 1 Level and Autophagy Function in TRAIL-Resistant Colon Cancer Cells. *Molecular Cancer Therapeutics*, **2019**, 18, 1265-1277	6.1	1
188	Generation of an induced pluripotent stem cell line (TRNDi004-I) from a Niemann-Pick disease type B patient carrying a heterozygous mutation of p.L43_A44delLA in the SMPD1 gene. *Stem Cell Research*, **2019**, 37, 101436	1.6	1
187	A human induced pluripotent stem cell line (TRNDi007-B) from an infantile onset Pompe patient carrying p.R854X mutation in the GAA gene. *Stem Cell Research*, **2019**, 37, 101435	1.6	7
186	High-Throughput Zika Viral Titer Assay for Rapid Screening of Antiviral Drugs. *Assay and Drug Development Technologies*, **2019**, 17, 128-139	2.1	6
185	An induced pluripotent stem cell line (TRNDi006-A) from a MPS IIIB patient carrying homozygous mutation of p.Glu153Lys in the NAGLU gene. *Stem Cell Research*, **2019**, 37, 101427	1.6	4

184	Generation of an induced pluripotent stem cell line (TRNDi005-A) from a Mucopolysaccharidosis Type IVA (MPS IVA) patient carrying compound heterozygous p.R61W and p.WT405del mutations in the GALNS gene. *Stem Cell Research*, **2019**, 36, 101408	1.6	3
183	Advancing precision medicine with personalized drug screening. *Drug Discovery Today*, **2019**, 24, 272-278	8.8	14
182	ERK Regulates HIF1Mediated Platinum Resistance by Directly Targeting PHD2 in Ovarian Cancer. *Clinical Cancer Research*, **2019**, 25, 5947-5960	12.9	19
181	An induced pluripotent stem cell line (TRNDi010-C) from a patient carrying a homozygous p.R401X mutation in the NGLY1 gene. *Stem Cell Research*, **2019**, 39, 101496	1.6	1
180	Quantitative Chemotherapeutic Profiling of Gynecologic Cancer Cell Lines Using Approved Drugs and Bioactive Compounds. *Translational Oncology*, **2019**, 12, 441-452	4.9	9
179	Generation of an induced pluripotent stem cell line (TRNDi003-A) from a Noonan syndrome with multiple lentigines (NSML) patient carrying a p.Q510P mutation in the PTPN11 gene. *Stem Cell Research*, **2019**, 34, 101374	1.6	6
178	Generation of an induced pluripotent stem cell line (TRNDi002-B) from a patient carrying compound heterozygous p.Q208X and p.G310G mutations in the NGLY1 gene. *Stem Cell Research*, **2019**, 34, 101362	1.6	5
177	Autocrine activation of JAK2 by IL-11 promotes platinum drug resistance. *Oncogene*, **2018**, 37, 3981-3997	7.2	17
176	Computer-Aided Discovery and Characterization of Novel Ebola Virus Inhibitors. *Journal of Medicinal Chemistry*, **2018**, 61, 3582-3594	8.3	21
175	Astrocytes as targets for drug discovery. *Drug Discovery Today*, **2018**, 23, 673-680	8.8	27
174	Neural stem cells for disease modeling and evaluation of therapeutics for infantile (CLN1/PPT1) and late infantile (CLN2/TPP1) neuronal ceroid lipofuscinoses. *Orphanet Journal of Rare Diseases*, **2018**, 13, 54	4.2	23
173	DUOXA1-mediated ROS production promotes cisplatin resistance by activating ATR-Chk1 pathway in ovarian cancer. *Cancer Letters*, **2018**, 428, 104-116	9.9	41
172	Drug repurposing screens and synergistic drug-combinations for infectious diseases. *British Journal of Pharmacology*, **2018**, 175, 181-191	8.6	111
171	Repurposing a novel parathyroid hormone analogue to treat hypoparathyroidism. *British Journal of Pharmacology*, **2018**, 175, 262-271	8.6	11
170	Small Molecules Identified from a Quantitative Drug Combinational Screen Resensitize CisplatinR Response in Drug-Resistant Ovarian Cancer Cells. *Translational Oncology*, **2018**, 11, 1053-1064	4.9	5
169	Patient iPSC-derived neural stem cells exhibit phenotypes in concordance with the clinical severity of mucopolysaccharidosis I. *Human Molecular Genetics*, **2018**, 27, 3612-3626	5.6	17
168	Pluripotent Stem Cell Platforms for Drug Discovery. *Trends in Molecular Medicine*, **2018**, 24, 805-820	11.5	24
167	Emetine inhibits Zika and Ebola virus infections through two molecular mechanisms: inhibiting viral replication and decreasing viral entry. *Cell Discovery*, **2018**, 4, 31	22.3	81

166	Drugging SUMOylation for neuroprotection and oncotherapy. *Neural Regeneration Research*, **2018**, 13, 415-416	4.5	8
165	Repurposing Screen Identifies Unconventional Drugs With Activity Against Multidrug Resistant. *Frontiers in Cellular and Infection Microbiology*, **2018**, 8, 438	5.9	18
164	Zika Virus: Origins, Pathological Action, and Treatment Strategies. *Frontiers in Microbiology*, **2018**, 9, 3253	3.7	24
163	Quantitative high-throughput screening identifies cytoprotective molecules that enhance SUMO conjugation via the inhibition of SUMO-specific protease (SENP)2. *FASEB Journal*, **2018**, 32, 1677-1691	0.9	22
162	Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space. *ACS Central Science*, **2018**, 4, 1727-1741	16.8	26
161	"Real-Time" High-Throughput Drug and Synergy Testing for Multidrug-Resistant Bacterial Infection: A Case Report. *Frontiers in Medicine*, **2018**, 5, 267	4.9	3
160	Neural stem cells for disease modeling and evaluation of therapeutics for Tay-Sachs disease. *Orphanet Journal of Rare Diseases*, **2018**, 13, 152	4.2	20
159	Metarrestin, a perinucleolar compartment inhibitor, effectively suppresses metastasis. *Science Translational Medicine*, **2018**, 10,	17.5	34
158	Optimization of the first small-molecule relaxin/insulin-like family peptide receptor (RXFP1) agonists: Activation results in an antifibrotic gene expression profile. *European Journal of Medicinal Chemistry*, **2018**, 156, 79-92	6.8	7
157	Methyl-□cyclodextrin restores impaired autophagy flux in Niemann-Pick C1-deficient cells through activation of AMPK. *Autophagy*, **2017**, 13, 1435-1451	10.2	52
156	Novel lead structures with both Plasmodium falciparum gametocytocidal and asexual blood stage activity identified from high throughput compound screening. *Malaria Journal*, **2017**, 16, 147	3.6	10
155	Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle. *Journal of Medicinal Chemistry*, **2017**, 60, 6364-6383	8.3	9
154	Analytical Characterization of Methyl-□Cyclodextrin for Pharmacological Activity to Reduce Lysosomal Cholesterol Accumulation in Niemann-Pick Disease Type C1 Cells. *Assay and Drug Development Technologies*, **2017**, 15, 154-166	2.1	10
153	Efficient Synthesis of 1,9-Substituted Benzo[h][1,6]naphthyridin-2(1H)-ones and Evaluation of their Plasmodium falciparum Gametocytocidal Activities. *ACS Combinatorial Science*, **2017**, 19, 748-754	3.9	4
152	Targeting Wolman Disease and Cholesteryl Ester Storage Disease: Disease Pathogenesis and Therapeutic Development. *Current Chemical Genomics and Translational Medicine*, **2017**, 11, 1-18		32
151	Dietary Fat Intake and Lung Cancer Risk: A Pooled Analysis. *Journal of Clinical Oncology*, **2017**, 35, 3055-3064	30.4	29
150	Identification of 4-phenylquinolin-2(1H)-one as a specific allosteric inhibitor of Akt. *Scientific Reports*, **2017**, 7, 11673	4.9	5
149	Drug discovery and development for rare genetic disorders. *American Journal of Medical Genetics, Part A*, **2017**, 173, 2307-2322	2.5	41

148	Neural stem cells for disease modeling of Wolman disease and evaluation of therapeutics. *Orphanet Journal of Rare Diseases*, **2017**, 12, 120	4.2	14
147	Synergistic drug combination effectively blocks Ebola virus infection. *Antiviral Research*, **2017**, 137, 165-172	6.8	58
146	Inhibition of PIP4K□ameliorates the pathological effects of mutant huntingtin protein. *ELife*, **2017**, 6,	8.9	30
145	Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen. *Nature Medicine*, **2016**, 22, 1101-1107	50.5	458
144	Molecular signatures associated with ZIKV exposure in human cortical neural progenitors. *Nucleic Acids Research*, **2016**, 44, 8610-8620	20.1	119
143	One-Step Seeding of Neural Stem Cells with Vitronectin-Supplemented Medium for High-Throughput Screening Assays. *Journal of Biomolecular Screening*, **2016**, 21, 1112-1124		10
142	A New Glucocerebrosidase Chaperone Reduces □Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism. *Journal of Neuroscience*, **2016**, 36, 7441-52	6.6	150
141	Rapid antimicrobial susceptibility test for identification of new therapeutics and drug combinations against multidrug-resistant bacteria. *Emerging Microbes and Infections*, **2016**, 5, e116	18.9	45
140	Identification of Multiple Cryptococcal Fungicidal Drug Targets by Combined Gene Dosing and Drug Affinity Responsive Target Stability Screening. *MBio*, **2016**, 7,	7.8	11
139	High throughput cell-based assay for identification of glycolate oxidase inhibitors as a potential treatment for Primary Hyperoxaluria Type 1. *Scientific Reports*, **2016**, 6, 34060	4.9	14
138	Rho GTPases: RAC1 polymorphisms affected platinum-based chemotherapy toxicity in lung cancer patients. *Cancer Chemotherapy and Pharmacology*, **2016**, 78, 249-58	3.5	10
137	A novel quantitative high-throughput screen identifies drugs that both activate SUMO conjugation via the inhibition of microRNAs 182 and 183 and facilitate neuroprotection in a model of oxygen and glucose deprivation. *Journal of Cerebral Blood Flow and Metabolism*, **2016**, 36, 426-41	7.3	23
136	Discovery, Optimization, and Characterization of Novel Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection. *Journal of Medicinal Chemistry*, **2016**, 59, 841-53	8.3	24
135	ML372 blocks SMN ubiquitination and improves spinal muscular atrophy pathology in mice. *JCI Insight*, **2016**, 1, e88427	9.9	13
134	Treatment Paradigms for Retinal and Macular Diseases Using 3-D Retina Cultures Derived From Human Reporter Pluripotent Stem Cell Lines **2016**, 57, ORSFl1-ORSFl11		30
133	A High-Throughput, Multi-Cell Phenotype Assay for the Identification of Novel Inhibitors of Chemotaxis/Migration. *Scientific Reports*, **2016**, 6, 22273	4.9	13
132	Drug combination therapy increases successful drug repositioning. *Drug Discovery Today*, **2016**, 21, 1189-95	6.5	159
131	High-Throughput Phenotypic Screening of Human Astrocytes to Identify Compounds That Protect Against Oxidative Stress. *Stem Cells Translational Medicine*, **2016**, 5, 613-27	6.9	25

130	In vitro evaluation of imidazo[4,5-c]quinolin-2-ones as gametocytocidal antimalarial agents. *Bioorganic and Medicinal Chemistry Letters*, **2016**, 26, 2907-2911	2.9	8
129	Induced Pluripotent Stem Cells for Disease Modeling and Evaluation of Therapeutics for Niemann-Pick Disease Type A. *Stem Cells Translational Medicine*, **2016**, 5, 1644-1655	6.9	20
128	Disease models for the development of therapies for lysosomal storage diseases. *Annals of the New York Academy of Sciences*, **2016**, 1371, 15-29	6.5	25
127	Mitochondrial DNA damage by bleomycin induces AML cell death. *Apoptosis: an International Journal on Programmed Cell Death*, **2015**, 20, 811-20	5.4	12
126	ERK and β-arrestin interaction: a converging point of signaling pathways for multiple types of cell surface receptors. *Journal of Biomolecular Screening*, **2015**, 20, 341-9		17
125	High-throughput viability assay using an autonomously bioluminescent cell line with a bacterial Lux reporter. *Journal of the Association for Laboratory Automation*, **2015**, 20, 164-74		15
124	Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection. *Science Translational Medicine*, **2015**, 7, 282ra49	17.5	95
123	Identification of novel anti-hepatitis C virus agents by a quantitative high throughput screen in a cell-based infection assay. *Antiviral Research*, **2015**, 124, 20-9	10.8	7
122	High-Throughput Screening, Discovery, and Optimization To Develop a Benzofuran Class of Hepatitis C Virus Inhibitors. *ACS Combinatorial Science*, **2015**, 17, 641-52	3.9	19
121	Maduramicin Rapidly Eliminates Malaria Parasites and Potentiates the Gametocytocidal Activity of the Pyrazoleamide PA21A050. *Antimicrobial Agents and Chemotherapy*, **2015**, 60, 1492-9	5.9	16
120	Elabela-apelin receptor signaling pathway is functional in mammalian systems. *Scientific Reports*, **2015**, 5, 8170	4.9	108
119	A cost-effective and efficient reprogramming platform for large-scale production of integration-free human induced pluripotent stem cells in chemically defined culture. *Scientific Reports*, **2015**, 5, 11319	4.9	82
118	Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia. *Cancer Cell*, **2015**, 27, 864-76	24.3	191
117	High-Throughput Screening to Identify Compounds That Increase Fragile X Mental Retardation Protein Expression in Neural Stem Cells Differentiated From Fragile X Syndrome Patient-Derived Induced Pluripotent Stem Cells. *Stem Cells Translational Medicine*, **2015**, 4, 800-8	6.9	62
116	Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents. *Breast Cancer Research*, **2015**, 17, 59	8.3	42
115	Chemical signatures and new drug targets for gametocytocidal drug development. *Scientific Reports*, **2014**, 4, 3743	4.9	67
114	Lomofungin and dilomofungin: inhibitors of MBNL1-CUG RNA binding with distinct cellular effects. *Nucleic Acids Research*, **2014**, 42, 6591-602	20.1	41
113	Discovery, optimization, and characterization of novel D2 dopamine receptor selective antagonists. *Journal of Medicinal Chemistry*, **2014**, 57, 3450-63	8.3	19

112	Discovery of novel antigiardiasis drug candidates. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 7303-11	5.9	23
111	A high-throughput screening assay for fungicidal compounds against Cryptococcus neoformans. *Journal of Biomolecular Screening*, **2014**, 19, 270-277		24
110	Novel cell-based hepatitis C virus infection assay for quantitative high-throughput screening of anti-hepatitis C virus compounds. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 995-1004	5.9	30
109	Inhibition of HERG potassium channels by domiphen bromide and didecyl dimethylammonium bromide. *European Journal of Pharmacology*, **2014**, 737, 202-9	5.3	2
108	Structural basis for inactivation of Giardia lamblia carbamate kinase by disulfiram. *Journal of Biological Chemistry*, **2014**, 289, 10502-10509	5.4	41
107	Niemann-Pick Disease Type C: Induced Pluripotent Stem Cell-Derived Neuronal Cells for Modeling Neural Disease and Evaluating Drug Efficacy. *Journal of Biomolecular Screening*, **2014**, 19, 1164-73		62
106	Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs. *Emerging Microbes and Infections*, **2014**, 3, e84	18.9	167
105	Macrophage models of Gaucher disease for evaluating disease pathogenesis and candidate drugs. *Science Translational Medicine*, **2014**, 6, 240ra73	17.5	72
104	A phenotypic compound screening assay for lysosomal storage diseases. *Journal of Biomolecular Screening*, **2014**, 19, 168-75		42
103	High-content screening identifies small molecules that remove nuclear foci, affect MBNL distribution and CELF1 protein levels via a PKC-independent pathway in myotonic dystrophy cell lines. *Human Molecular Genetics*, **2014**, 23, 1551-62	5.6	48
102	A high throughput screening assay system for the identification of small molecule inhibitors of gsp. *PLoS ONE*, **2014**, 9, e90766	3.7	13
101	Collaborative development of 2-hydroxypropyl-β-cyclodextrin for the treatment of Niemann-Pick type C1 disease. *Current Topics in Medicinal Chemistry*, **2014**, 14, 330-9	3	94
100	A high-throughput screening assay for assessing the viability of Cryptococcus neoformans under nutrient starvation conditions. *Analytical and Bioanalytical Chemistry*, **2013**, 405, 6823-9	4.4	7
99	Phenotypic screens as a renewed approach for drug discovery. *Drug Discovery Today*, **2013**, 18, 1067-73	8.8	282
98	Induction and reversal of myotonic dystrophy type 1 pre-mRNA splicing defects by small molecules. *Nature Communications*, **2013**, 4, 2044	17.4	68
97	Identification and optimization of small-molecule agonists of the human relaxin hormone receptor RXFP1. *Nature Communications*, **2013**, 4, 1953	17.4	47
96	Structure-activity relationship of imidazopyridinium analogues as antagonists of neuropeptide s receptor. *Journal of Medicinal Chemistry*, **2013**, 56, 9045-56	8.3	15
95	A quantitative high throughput assay for identifying gametocytocidal compounds. *Molecular and Biochemical Parasitology*, **2013**, 188, 20-5	1.9	40

94	Mechanism of HERG potassium channel inhibition by tetra-n-octylammonium bromide and benzethonium chloride. *Toxicology and Applied Pharmacology*, **2013**, 267, 155-66	4.6	7
93	A novel brain penetrant NPS receptor antagonist, NCGC00185684, blocks alcohol-induced ERK-phosphorylation in the central amygdala and decreases operant alcohol self-administration in rats. *Journal of Neuroscience*, **2013**, 33, 10132-42	6.6	23
92	Identification of small-molecule agonists of human relaxin family receptor 1 (RXFP1) by using a homogenous cell-based cAMP assay. *Journal of Biomolecular Screening*, **2013**, 18, 670-7		20
91	An alternative direct compound dispensing method using the HP D300 digital dispenser. *Journal of the Association for Laboratory Automation*, **2013**, 18, 367-74		21
90	Identification of a selective small-molecule inhibitor series targeting the eyes absent 2 (Eya2) phosphatase activity. *Journal of Biomolecular Screening*, **2013**, 18, 85-96		27
89	Rapid identification of antifungal compounds against Exserohilum rostratum using high throughput drug repurposing screens. *PLoS ONE*, **2013**, 8, e70506	3.7	20
88	A high-throughput screening assay for determining cellular levels of total tau protein. *Current Alzheimer Research*, **2013**, 10, 679-87	3	20
87	A high throughput glucocerebrosidase assay using the natural substrate glucosylceramide. *Analytical and Bioanalytical Chemistry*, **2012**, 402, 731-9	4.4	23
86	Two high-throughput screening assays for aberrant RNA-protein interactions in myotonic dystrophy type 1. *Analytical and Bioanalytical Chemistry*, **2012**, 402, 1889-98	4.4	40
85	Plasma and tissue concentrations of □-tocopherol and □-tocopherol following high dose dietary supplementation in mice. *Nutrients*, **2012**, 4, 467-90	6.7	19
84	Non-iminosugar glucocerebrosidase small molecule chaperones. *MedChemComm*, **2012**, 3, 56-60	5	20
83	Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1-CBF□ interaction. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 14592-7	11.5	81
82	Discovery of a novel noniminosugar acid □-glucosidase chaperone series. *Journal of Medicinal Chemistry*, **2012**, 55, 7546-59	8.3	21
81	Discovery, structure-activity relationship, and biological evaluation of noninhibitory small molecule chaperones of glucocerebrosidase. *Journal of Medicinal Chemistry*, **2012**, 55, 5734-48	8.3	93
80	A high-throughput sphingomyelinase assay using natural substrate. *Analytical and Bioanalytical Chemistry*, **2012**, 404, 407-14	4.4	7
79	Evaluation of cholesterol reduction activity of methyl-□-cyclodextrin using differentiated human neurons and astrocytes. *Journal of Biomolecular Screening*, **2012**, 17, 1243-51		15
78	□-Tocopherol reduces lipid accumulation in Niemann-Pick type C1 and Wolman cholesterol storage disorders. *Journal of Biological Chemistry*, **2012**, 287, 39349-60	5.4	93
77	High throughput screening for small molecule therapy for Gaucher disease using patient tissue as the source of mutant glucocerebrosidase. *PLoS ONE*, **2012**, 7, e29861	3.7	51

76	High-Throughput Multiplexed Quantitation of Protein Aggregation and Cytotoxicity in a Huntington's Disease Model. *Current Chemical Genomics*, **2012**, 6, 79-86		21
75	A homogenous luminescence assay reveals novel inhibitors for giardia lamblia carbamate kinase. *Current Chemical Genomics*, **2012**, 6, 93-102		13
74	Discovery, synthesis, and biological evaluation of novel SMN protein modulators. *Journal of Medicinal Chemistry*, **2011**, 54, 6215-33	8.3	37
73	Evaluation of quinazoline analogues as glucocerebrosidase inhibitors with chaperone activity. *Journal of Medicinal Chemistry*, **2011**, 54, 1033-58	8.3	54
72	Novel patient cell-based HTS assay for identification of small molecules for a lysosomal storage disease. *PLoS ONE*, **2011**, 6, e29504	3.7	10
71	Identification of quaternary ammonium compounds as potent inhibitors of hERG potassium channels. *Toxicology and Applied Pharmacology*, **2011**, 252, 250-8	4.6	29
70	Phosphodiesterase 4 inhibitors enhance sexual pleasure-seeking activity in rodents. *Pharmacology Biochemistry and Behavior*, **2011**, 98, 349-55	3.9	2
69	The Synthesis and Evaluation of Dihydroquinazolin-4-ones and Quinazolin-4-ones as Thyroid Stimulating Hormone Receptor Agonists. *MedChemComm*, **2011**, 2, 1016-1020	5	7
68	High-throughput Giardia lamblia viability assay using bioluminescent ATP content measurements. *Antimicrobial Agents and Chemotherapy*, **2011**, 55, 667-75	5.9	35
67	Fabry disease - current treatment and new drug development. *Current Chemical Genomics*, **2010**, 4, 50-6		32
66	High throughput screening for inhibitors of alpha-galactosidase. *Current Chemical Genomics*, **2010**, 4, 67-73		13
65	Selective Modulation of Gq/Gs pathways by Naphtho Pyrano Pyrimidines as antagonists of the Neuropeptide S Receptor. *ACS Chemical Neuroscience*, **2010**, 1, 559-574	5.7	24
64	A multiplex calcium assay for identification of GPCR agonists and antagonists. *Assay and Drug Development Technologies*, **2010**, 8, 367-79	2.1	24
63	Evaluation of 2-thioxo-2,3,5,6,7,8-hexahydropyrimido[4,5-d]pyrimidin-4(1H)-one analogues as GAA activators. *European Journal of Medicinal Chemistry*, **2010**, 45, 1880-97	6.8	21
62	Small Molecule Drug Discovery for Fabry Disease **2010**, 163-177		
61	The pilot phase of the NIH Chemical Genomics Center. *Current Topics in Medicinal Chemistry*, **2009**, 9, 1181-93	3	24
60	An AlphaScreen-based high-throughput screen to identify inhibitors of Hsp90-cochaperone interaction. *Journal of Biomolecular Screening*, **2009**, 14, 273-81		42
59	Small-molecule agonists for the thyrotropin receptor stimulate thyroid function in human thyrocytes and mice. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 12471-6	11.5	85

58	Cardiac glycosides inhibit p53 synthesis by a mechanism relieved by Src or MAPK inhibition. *Cancer Research*, **2009**, 69, 6556-64	10.1	80
57	Automated high-content screening for compounds that disassemble the perinucleolar compartment. *Journal of Biomolecular Screening*, **2009**, 14, 1045-53		17
56	Synthesis and characterization of a new fluorogenic substrate for alpha-galactosidase. *Analytical and Bioanalytical Chemistry*, **2009**, 394, 1903-9	4.4	11
55	Quantitative high-throughput screening identifies inhibitors of anthrax-induced cell death. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 5139-45	3.4	28
54	A new resorufin-based alpha-glucosidase assay for high-throughput screening. *Analytical Biochemistry*, **2009**, 390, 79-84	3.1	21
53	A new homogeneous high-throughput screening assay for profiling compound activity on the human ether-a-go-go-related gene channel. *Analytical Biochemistry*, **2009**, 394, 30-8	3.1	52
52	Multi-gram scale synthesis of FR180204. *Journal of Organic Chemistry*, **2009**, 74, 8870-3	4.2	18
51	Screening Automation. *Critical Reviews in Combinatorial Chemistry*, **2009**,		1
50	A robotic platform for quantitative high-throughput screening. *Assay and Drug Development Technologies*, **2008**, 6, 637-57	2.1	111
49	Quantitative high-throughput screening using a live-cell cAMP assay identifies small-molecule agonists of the TSH receptor. *Journal of Biomolecular Screening*, **2008**, 13, 120-7		47
48	A cell-based PDE4 assay in 1536-well plate format for high-throughput screening. *Journal of Biomolecular Screening*, **2008**, 13, 609-18		20
47	Compound Management for Quantitative High-Throughput Screening. *Journal of the Association for Laboratory Automation*, **2008**, 13, 79-89		68
46	A miniaturized glucocorticoid receptor translocation assay using enzymatic fragment complementation evaluated with qHTS. *Combinatorial Chemistry and High Throughput Screening*, **2008**, 11, 545-59	1.3	14
45	Optimization and validation of two miniaturized glucocerebrosidase enzyme assays for high throughput screening. *Combinatorial Chemistry and High Throughput Screening*, **2008**, 11, 817-24	1.3	31
44	Comparison on functional assays for Gq-coupled GPCRs by measuring inositol monophospate-1 and intracellular calcium in 1536-well plate format. *Current Chemical Genomics*, **2008**, 1, 70-8		28
43	N4-phenyl modifications of N2-(2-hydroxyl)ethyl-6-(pyrrolidin-1-yl)-1,3,5-triazine-2,4-diamines enhance glucocerebrosidase inhibition by small molecules with potential as chemical chaperones for Gaucher disease. *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 5783-9	2.9	26
42	High-throughput screening assays for the identification of chemical probes. *Nature Chemical Biology*, **2007**, 3, 466-79	11.7	478
41	Evaluation of micro-parallel liquid chromatography as a method for HTS-coupled actives verification. *Assay and Drug Development Technologies*, **2007**, 5, 815-24	2.1	4

40	Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 13192-7	11.5	130
39	A cell-based ultra-high-throughput screening assay for identifying inhibitors of D-amino acid oxidase. *Journal of Biomolecular Screening*, **2006**, 11, 481-7		42
38	Kv1.3 Potassium Channel: Physiology, Pharmacology and Therapeutic Indications. *Methods and Principles in Medicinal Chemistry*, **2006**, 214-274	0.4	7
37	Drugs Active at ATP-sensitive K+ Channels. *Methods and Principles in Medicinal Chemistry*, **2006**, 335-354	0.4	2
36	Drugs Active at Kv1.5 Potassium Channels [1]. *Methods and Principles in Medicinal Chemistry*, **2006**, 275-309	0.4	1
35	Compounds that Activate KCNQ(2-5) Family of Potassium Ion Channels. *Methods and Principles in Medicinal Chemistry*, **2006**, 355-380	0.4	1
34	Potassium Channels: Overview of Molecular, Biophysical and Pharmacological Properties. *Methods and Principles in Medicinal Chemistry*, **2006**, 193-213	0.4	
33	Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 11473-8	11.5	632
32	Medicinal Chemistry of Ca2+-activated K+ Channel Modulators. *Methods and Principles in Medicinal Chemistry*, **2006**, 310-334	0.4	6
31	Introduction To Ion Channels. *Methods and Principles in Medicinal Chemistry*, **2006**, 1-5	0.4	
30	The Voltage-Gated Ion Channel Superfamily. *Methods and Principles in Medicinal Chemistry*, **2006**, 7-18	0.4	
29	State-Dependent Drug Interactions with Ion Channels. *Methods and Principles in Medicinal Chemistry* , **2006**, 19-36	0.4	3
28	Assay Technologies: Techniques Available for Quantifying Drug-Channel Interactions. *Methods and Principles in Medicinal Chemistry*, **2006**, 37-63	0.4	2
27	Overview of Voltage-gated Calcium Channels. *Methods and Principles in Medicinal Chemistry*, **2006**, 65-83	0.4	
26	Drugs Active at T-type Ca2+ Channels. *Methods and Principles in Medicinal Chemistry*, **2006**, 84-99	0.4	1
25	Fluorescent protein-based cellular assays analyzed by laser-scanning microplate cytometry in 1536-well plate format. *Methods in Enzymology*, **2006**, 414, 566-89	1.7	24
24	Inherited Disorders of Ion Channels. *Methods and Principles in Medicinal Chemistry*, **2006**, 381-427	0.4	5
23	N-type Calcium Channels. *Methods and Principles in Medicinal Chemistry*, **2006**, 122-149	0.4	

22	Molecular, Biophysical and Functional Properties of Voltage-gated Sodium Channels. *Methods and Principles in Medicinal Chemistry*, **2006**, 151-167	0.4	
21	Ion Channel Safety Issues in Drug Development. *Methods and Principles in Medicinal Chemistry*, **2006** , 444-465	0.4	3
20	L-type Calcium Channels. *Methods and Principles in Medicinal Chemistry*, **2006**, 100-121	0.4	3
19	Small Molecule Blockers of Voltage-gated Sodium Channels. *Methods and Principles in Medicinal Chemistry*, **2006**, 168-192	0.4	3
18	Structural and Ligand-based Models for HERG and their Application in Medicinal Chemistry. *Methods and Principles in Medicinal Chemistry*, **2006**, 428-443	0.4	3
17	Identification of small molecule antagonists of the human mas-related gene-X1 receptor. *Analytical Biochemistry*, **2006**, 351, 50-61	3.1	24
16	High-throughput screening of 11beta-hydroxysteroid dehydrogenase type 1 in scintillation proximity assay format. *Assay and Drug Development Technologies*, **2005**, 3, 377-84	2.1	10
15	A short-incubation reporter-gene assay for high-throughput screening of estrogen receptor-alpha antagonists. *Assay and Drug Development Technologies*, **2005**, 3, 393-400	2.1	5
14	Application of division arrest technology to cell-based HTS: comparison with frozen and fresh cells. *Assay and Drug Development Technologies*, **2005**, 3, 17-26	2.1	34
13	A 1536-well cAMP assay for Gs- and Gi-coupled receptors using enzyme fragmentation complementation. *Assay and Drug Development Technologies*, **2004**, 2, 39-49	2.1	25
12	High-throughput cell-based screening using scintillation proximity assay for the discovery of inositol phosphatase inhibitors. *Journal of Biomolecular Screening*, **2004**, 9, 132-40		10
11	High throughput assay technologies for ion channel drug discovery. *Assay and Drug Development Technologies*, **2004**, 2, 543-52	2.1	110
10	Application of real-time cell electronic sensing (RT-CES) technology to cell-based assays. *Assay and Drug Development Technologies*, **2004**, 2, 363-72	2.1	316
9	Scintillation proximity assay of inositol phosphates in cell extracts: high-throughput measurement of G-protein-coupled receptor activation. *Analytical Biochemistry*, **2003**, 313, 311-8	3.1	75
8	A collaborative screening program for the discovery of inhibitors of HCV NS2/3 cis-cleaving protease activity. *Journal of Biomolecular Screening*, **2002**, 7, 149-54		27
7	2-Arylindole-3-acetamides: FPP-competitive inhibitors of farnesyl protein transferase. *Bioorganic and Medicinal Chemistry Letters*, **2001**, 11, 865-9	2.9	14
6	Miniaturization of a hepatitis C virus RNA polymerase assay using a -102 degrees C cooled CCD camera-based imaging system. *Analytical Biochemistry*, **2001**, 290, 214-20	3.1	22
5	Characterization of calcium channel binding. *Current Protocols in Pharmacology*, **2001**, Chapter 1, Unit1.25	4.1	

4	Identification and characterization of small molecule functional antagonists of the CCR1 chemokine receptor. *Journal of Biological Chemistry*, **1998**, 273, 15687-92	5.4	111
3	Increased expression of the cardiac L-type calcium channel in estrogen receptor-deficient mice. *Journal of General Physiology*, **1997**, 110, 135-40	3.4	150
2	Thermodynamic and kinetic aspects of agonist and antagonist binding to 1,4-dihydropyridine receptors. *European Journal of Pharmacology*, **1991**, 208, 137-47		6
1	Preclinical Pharmacokinetics and In Vitro Properties of GS-441524, A Potential Oral Drug Candidate for COVID-19 Treatment		1